Dermapharm AG
Dermapharm AG, headquartered in Germany, is a prominent player in the pharmaceutical industry, specialising in the development and production of high-quality generic and specialty medications. Founded in 1991, the company has established a strong presence across Europe, with significant operations in various key markets. With a diverse portfolio that includes prescription drugs, over-the-counter products, and active pharmaceutical ingredients, Dermapharm AG is recognised for its commitment to innovation and quality. The company’s unique approach to product development and its focus on niche therapeutic areas set it apart from competitors. Dermapharm AG has achieved notable milestones, including strategic acquisitions that have expanded its market reach and enhanced its product offerings. As a trusted name in the pharmaceutical sector, Dermapharm AG continues to uphold its reputation for excellence and reliability in healthcare solutions.
DitchCarbon Score
How does Dermapharm AG's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Dermapharm AG's score of 22 is lower than 78% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Dermapharm AG's reported carbon emissions
Dermapharm AG, headquartered in Germany, currently does not report specific carbon emissions data for the most recent year, as indicated by the absence of emissions figures. The company is a current subsidiary of Dermapharm Holding SE, which may influence its climate-related initiatives and reporting. While Dermapharm AG has not established specific reduction targets or commitments under the Science Based Targets initiative (SBTi), it is important to note that emissions data may be inherited from its parent company, Dermapharm Holding SE, which operates within the pharmaceutical sector. This industry is increasingly focused on sustainability and reducing carbon footprints, although specific initiatives or targets from Dermapharm AG itself have not been disclosed. As a subsidiary, Dermapharm AG may align its climate strategies with broader corporate goals set by Dermapharm Holding SE, but detailed information on these initiatives is not available at this time. The company’s commitment to addressing climate change remains unclear without specific emissions data or reduction targets.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Dermapharm AG is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
